Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 6:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1705–1728 of 22,463 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pathological Processes Clear all
Not listed Not applicable Interventional Accepts healthy volunteers

Down Syndrome - Comparison of Screening Methods in the 1st and 2nd Trimesters

NCT00006445
View directory record Official record
Conditions
Down Syndrome, Chromosome Abnormalities
Interventions
Ultrasound, Serum screen
Procedure
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
16 Years to 45 Years · Female only
Enrollment
38,000 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
10
States / cities
Denver, Colorado • Boston, Massachusetts • Royal Oak, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2007 · Synced Oct 29, 2026, 6:03 AM EDT
Completed Phase 1 Interventional Results available

A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia

NCT02011945
View directory record Official record
Conditions
Chronic Myeloid Leukemia
Interventions
Dasatinib, Nivolumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
5
States / cities
Atlanta, Georgia • Boston, Massachusetts • Dallas, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2020 · Synced Oct 29, 2026, 6:03 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Phase I/II Study of Intratumoral Injection of SD-101

NCT02254772
View directory record Official record
Conditions
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Splenic Marginal Zone Lymphoma
Interventions
Ipilimumab, SD-101, Radiation therapy
Biological · Drug · Radiation
Lead sponsor
Robert Lowsky
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 29, 2026, 6:03 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Performance Assessment of the PMD-200 Under General Anesthesia

NCT03467230
View directory record Official record
Conditions
Pain, Opioid Use, Intraoperative Complications
Interventions
NoL Index
Device
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Oct 29, 2026, 6:03 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Preliminary Study of CA-008 (Vocacapsaicin) in Patients Undergoing Ventral Hernia Repair

NCT04774328
View directory record Official record
Conditions
Postsurgical Pain
Interventions
CA-008 (vocacapsaicin), Placebo
Drug
Lead sponsor
Concentric Analgesics
Industry
Eligibility
18 Years to 80 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 14, 2022 · Synced Oct 29, 2026, 6:03 AM EDT
Completed Not applicable Interventional Results available

Prospective Study to Investigate the Frequency of Possible Bacterial Entry Into the Bloodstream (Bacteremia) and Infectious Complications Associated With the Use of the Spyglass Cholangioscopy System During ERCP (Endoscopic Retrograde Cholangiopancreatography).

NCT01414400
View directory record Official record
Conditions
Bile Duct Stricture, Choledocholithiasis
Interventions
Blood draw for culture
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 14, 2025 · Synced Oct 29, 2026, 6:03 AM EDT
Completed Phase 4 Interventional

A Peri-intubation Oral Intervention to Reduce Oral Flora and VAP

NCT00248300
View directory record Official record
Conditions
Pneumonia
Interventions
Chlorhexidine
Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 11, 2015 · Synced Oct 29, 2026, 6:03 AM EDT
Completed Phase 1 Interventional

AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR

NCT00770536
View directory record Official record
Conditions
Cancer, Carcinoma, Fallopian Tube Cancer, Gynecological Malignancies, Metastases, Oncology, Ovarian Cancer, Solid Tumors, Tumors
Interventions
A1: AMG 386 10 mg/kg + Liposomal doxorubicin, A3: AMG 386 15mg/kg + Liposomal doxorubicin, B1: AMG 386 10 mg/kg + Topotecan, B3: AMG 386 15mg/kg + Topotecan
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older · Female only
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
9
States / cities
Tucson, Arizona • Sacramento, California • Orlando, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2015 · Synced Oct 29, 2026, 6:03 AM EDT
Withdrawn Phase 1 Interventional

Alsertib (MLN8237) and Brentuximab Vedotin for Relapsed/Refractory CD30-Positive Lymphomas and Solid Malignancies

NCT02780011
View directory record Official record
Conditions
CD30-positive Lymphoma, CD30-positive Solid Tumor
Interventions
Brentuximab Vedotin, Alsertib
Drug
Lead sponsor
Eric Bernicker, MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 27, 2018 · Synced Oct 29, 2026, 6:03 AM EDT
Terminated Phase 1 Interventional Results available

The Using Postoperative Ketamine and Exploring the Effect on Endometriosis Pain (UPKEEEP) Study

NCT05229653
View directory record Official record
Conditions
Endometriosis, Post Operative Pain
Interventions
Ketamine, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Oct 29, 2026, 6:03 AM EDT
Completed Phase 4 Interventional Results available

The Effect of Choice of Intraoperative Opioid on Postoperative Pain

NCT01542645
View directory record Official record
Conditions
Pain, Postoperative, Chronic Pain
Interventions
Methadone, Fentanyl
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years to 90 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Oct 29, 2026, 6:03 AM EDT
Completed Phase 4 Interventional Results available

Continuous Oral Contraceptive Treatment in Premenstrual Dysphoric Disorder (PMDD)

NCT00927095
View directory record Official record
Conditions
Premenstrual Dysphoric Disorder
Interventions
Continuous OC (EE/DROS), Intermittent OC (EE/DROS), placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 52 Years · Female only
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 24, 2016 · Synced Oct 29, 2026, 6:03 AM EDT
Not yet recruiting Phase 4 Interventional

Mechanistic Evaluation of Atrasentan in Patients With IgA Nephropathy (IgAN)

NCT07820995
View directory record Official record
Conditions
IgA Nephropathy (IgAN), Immunoglobulin A Nephropathy (IgAN)
Interventions
atrasentan
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 29, 2026, 6:03 AM EDT
Recruiting Phase 2 Interventional

Study of Seladelpar and Cilofexor in Participants With Primary Biliary Cholangitis

NCT07841977
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
Seladelpar, PTM Seladelpar, Cilofexor Dose B, PTM Cilofexor Dose A, PTM Cilofexor Dose B, Cilofexor Dose A
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
4
States / cities
Colorado Springs, Colorado • Lakewood Rch, Florida • Atlanta, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 29, 2026, 6:03 AM EDT
Recruiting Phase 2 Interventional

Circulating Tumor DNA Response In Urothelial Cancer

NCT07183319
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
Pembrolizumab & Enfortumab Vedotin (PEV), Pembrolizumab
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 29, 2026, 6:03 AM EDT
Completed Phase 3 Interventional

A Phase III, Open Label, Randomized, Controlled Study of VBI-S in the Treatment of Hypovolemia in Patients With Septic Shock (VBI-S-02)

NCT06072430
View directory record Official record
Conditions
Septic Shock, Sepsis, Hypovolemia
Interventions
VBI-S
Drug
Lead sponsor
Vivacelle Bio
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
5
States / cities
Chandler, Arizona • Savannah, Georgia • Kansas City, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 29, 2026, 6:03 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Metabolic Syndrome, Inflammation, and Risk of Cognitive Decline

NCT00099567
View directory record Official record
Conditions
Cognitive Decline
Interventions
Not listed
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
70 Years to 79 Years
Enrollment
2,632 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2002
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 1, 2005 · Synced Oct 29, 2026, 6:03 AM EDT
Terminated Not applicable Interventional Results available

Video Capsule Endoscopy Versus Colonoscopy in Patients With Melena and Negative Upper Endoscopy

NCT02609100
View directory record Official record
Conditions
Gastrointestinal Hemorrhage
Interventions
Video Capsule Endoscopy, Colonoscopy, 1.0 X 2.5 cm 'pill' containing a camera
Procedure · Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 20, 2018 · Synced Oct 29, 2026, 6:03 AM EDT
Completed Phase 1 Interventional

Aerosol Cyclosporine in Chronic Obstructive Pulmonary Disease (COPD)

NCT00783107
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Cyclosporine, Placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
45 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 11, 2012 · Synced Oct 29, 2026, 6:03 AM EDT
Completed Phase 3 Interventional

Treatment of Chronic Granulomatous Disease With Allogeneic Stem Cell Transplantation Versus Standard of Care

NCT00023192
View directory record Official record
Conditions
Chronic Granulomatous Disease
Interventions
T-Cell Depleted & CD34+Select/w/StemCell Enriched Product
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 29, 2026, 6:03 AM EDT
Terminated Phase 1 Interventional

Phase I Trial of IV Fenretinide (4-HPR) Plus IV Safingol for Patients With Relapsed Malignancies

NCT01553071
View directory record Official record
Conditions
Solid Tumor
Interventions
Fenretinide (4-HPR) plus Intravenous Safingol
Drug
Lead sponsor
South Plains Oncology Consortium
Network
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
3
States / cities
Dallas, Texas • Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 29, 2026, 6:03 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.

NCT04463771
View directory record Official record
Conditions
Endometrial Cancer
Interventions
retifanlimab, epacadostat, pemigatinib, INCAGN02385, INCAGN02390
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older · Female only
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
29
States / cities
Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 29, 2026, 6:03 AM EDT
Terminated Phase 2 Interventional

Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas

NCT04305444
View directory record Official record
Conditions
Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Richter's Transformation
Interventions
DTRM-555
Drug
Lead sponsor
Zhejiang DTRM Biopharma
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
8
States / cities
Phoenix, Arizona • New Haven, Connecticut • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Oct 29, 2026, 6:03 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease

NCT04492722
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
AZD5718, Dapagliflozin 10 mg, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
613 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
22
States / cities
Canoga Park, California • La Mesa, California • San Carlos, California + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2024 · Synced Oct 29, 2026, 6:03 AM EDT